SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ immunology
Apolipoprotein A-I
/ chemistry
Autoantibodies
/ immunology
COVID-19
/ immunology
Computational Biology
Cytokines
/ immunology
Epitopes
/ chemistry
Female
Humans
Immunity, Humoral
/ immunology
Immunoglobulin G
/ immunology
Male
Middle Aged
Peptide Fragments
/ chemistry
Peptides
SARS-CoV-2
Sequence Homology, Amino Acid
Spike Glycoprotein, Coronavirus
/ chemistry
Toll-Like Receptor 2
/ chemistry
Young Adult
COVID-19
anti-apolipoprotein A-1 autoantibodies
molecular mimicry
spike protein
toll-like receptor 2
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
21
07
2021
received:
29
06
2021
accepted:
23
07
2021
pubmed:
30
7
2021
medline:
6
11
2021
entrez:
29
7
2021
Statut:
ppublish
Résumé
Unravelling autoimmune targets triggered by SARS-CoV-2 infection may provide crucial insights into the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We aimed at determining (a) the association between anti-SARS-CoV-2 and anti-apoA-1 humoral response and (b) the degree of linear homology between SARS-CoV-2, apoA-1 and Toll-like receptor 2 (TLR2) epitopes. Bioinformatics modelling coupled with mimic peptides engineering and competition experiments were used to assess epitopes sequence homologies. Anti-SARS-CoV-2 and anti-apoA-1 IgG as well as cytokines were assessed by immunoassays on a case-control (n = 101), an intensive care unit (ICU; n = 126) and a general population cohort (n = 663) with available samples in the pre and post-pandemic period. Using bioinformatics modelling, linear sequence homologies between apoA-1, TLR2 and Spike epitopes were identified but without experimental evidence of cross-reactivity. Overall, anti-apoA-1 IgG levels were higher in COVID-19 patients or anti-SARS-CoV-2 seropositive individuals than in healthy donors or anti-SARS-CoV-2 seronegative individuals (P < .0001). Significant and similar associations were noted between anti-apoA-1, anti-SARS-CoV-2 IgG, cytokines and lipid profile. In ICU patients, anti-SARS-CoV-2 and anti-apoA-1 seroconversion rates displayed similar 7-day kinetics, reaching 82% for anti-apoA-1 seropositivity. In the general population, SARS-CoV-2-exposed individuals displayed higher anti-apoA-1 IgG seropositivity rates than nonexposed ones (34% vs 16.8%; P = .004). COVID-19 induces a marked humoral response against the major protein of high-density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long-term COVID-19 prognosis assessment and warrant further scrutiny in the current COVID-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
Unravelling autoimmune targets triggered by SARS-CoV-2 infection may provide crucial insights into the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We aimed at determining (a) the association between anti-SARS-CoV-2 and anti-apoA-1 humoral response and (b) the degree of linear homology between SARS-CoV-2, apoA-1 and Toll-like receptor 2 (TLR2) epitopes.
DESIGN
METHODS
Bioinformatics modelling coupled with mimic peptides engineering and competition experiments were used to assess epitopes sequence homologies. Anti-SARS-CoV-2 and anti-apoA-1 IgG as well as cytokines were assessed by immunoassays on a case-control (n = 101), an intensive care unit (ICU; n = 126) and a general population cohort (n = 663) with available samples in the pre and post-pandemic period.
RESULTS
RESULTS
Using bioinformatics modelling, linear sequence homologies between apoA-1, TLR2 and Spike epitopes were identified but without experimental evidence of cross-reactivity. Overall, anti-apoA-1 IgG levels were higher in COVID-19 patients or anti-SARS-CoV-2 seropositive individuals than in healthy donors or anti-SARS-CoV-2 seronegative individuals (P < .0001). Significant and similar associations were noted between anti-apoA-1, anti-SARS-CoV-2 IgG, cytokines and lipid profile. In ICU patients, anti-SARS-CoV-2 and anti-apoA-1 seroconversion rates displayed similar 7-day kinetics, reaching 82% for anti-apoA-1 seropositivity. In the general population, SARS-CoV-2-exposed individuals displayed higher anti-apoA-1 IgG seropositivity rates than nonexposed ones (34% vs 16.8%; P = .004).
CONCLUSION
CONCLUSIONS
COVID-19 induces a marked humoral response against the major protein of high-density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long-term COVID-19 prognosis assessment and warrant further scrutiny in the current COVID-19 pandemic.
Identifiants
pubmed: 34324704
doi: 10.1111/eci.13661
pmc: PMC8420318
doi:
Substances chimiques
Antibodies, Viral
0
Apolipoprotein A-I
0
Autoantibodies
0
Cytokines
0
Epitopes
0
Immunoglobulin G
0
Peptide Fragments
0
Peptides
0
Spike Glycoprotein, Coronavirus
0
TLR2 protein, human
0
Toll-Like Receptor 2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13661Subventions
Organisme : Fondation Ancrage
Organisme : Fondation Ernst et Lucie Schmidheiny
Organisme : The De Reuter
ID : 657
Organisme : Swiss Federal Office of Public Health
Organisme : Fondation Privée des HUG
Organisme : Center for Emerging Viral Diseases
Organisme : Fondation de Bienfaisance du Groupe Pictet
Informations de copyright
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
PLoS One. 2020 Sep 24;15(9):e0239573
pubmed: 32970772
Thromb Haemost. 2016 Sep 27;116(4):764-71
pubmed: 27384400
Cell. 2007 Sep 21;130(6):1071-82
pubmed: 17889651
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):754-759
pubmed: 32723434
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Curr Opin Infect Dis. 2009 Feb;22(1):49-56
pubmed: 19532080
Pol Arch Intern Med. 2020 May 29;130(5):400-406
pubmed: 32356642
J Biol Chem. 2003 Feb 28;278(9):6719-30
pubmed: 12488454
PLoS One. 2020 Sep 9;15(9):e0238089
pubmed: 32903266
J Clin Med. 2019 Nov 21;8(12):
pubmed: 31766415
Ann Rheum Dis. 2020 Dec;79(12):1661-1663
pubmed: 32581086
Hepatol Int. 2018 Jan;12(1):17-25
pubmed: 29423541
J Diabetes Complications. 2016 May-Jun;30(4):580-5
pubmed: 26965796
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Eur J Clin Invest. 2020 Oct;50(10):e13357
pubmed: 32691863
J Infect Dis. 2020 Oct 1;222(9):1439-1443
pubmed: 32738141
Nature. 2021 Feb;590(7844):29-31
pubmed: 33469204
J Thromb Haemost. 2021 May;19(5):1342-1347
pubmed: 33639037
Endocrinology. 2015 Dec;156(12):4707-19
pubmed: 26393305
J Intern Med. 2012 Oct;272(4):344-57
pubmed: 22329401
Front Immunol. 2020 Oct 15;11:584241
pubmed: 33178218
J Biol Chem. 2014 Oct 10;289(41):28249-59
pubmed: 25170076
Front Immunol. 2017 Apr 18;8:437
pubmed: 28458671
J Neurol. 2021 Mar;268(3):751-757
pubmed: 32734353
Thromb Haemost. 2015 Aug;114(2):410-22
pubmed: 25879306
Clin Transl Immunology. 2020 Dec 14;9(12):e1220
pubmed: 33343896
Nat Metab. 2020 Dec;2(12):1391-1400
pubmed: 33244168
Viruses. 2019 Aug 19;11(8):
pubmed: 31430946
PLoS One. 2015 Jul 15;10(7):e0132780
pubmed: 26177543
Sci Rep. 2020 Aug 25;10(1):14179
pubmed: 32843695
J Transl Autoimmun. 2021;4:100100
pubmed: 33880442
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Lipids Health Dis. 2020 Sep 7;19(1):204
pubmed: 32892746
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249
pubmed: 33372199
Eur J Clin Invest. 2021 Nov;51(11):e13661
pubmed: 34324704
J Clin Med. 2019 Jul 09;8(7):
pubmed: 31324073
Cardiovasc Res. 2017 Aug 1;113(10):1102-1112
pubmed: 28899001
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2342-2349
pubmed: 29074586
PLoS Pathog. 2016 May 06;12(5):e1005610
pubmed: 27152966
Signal Transduct Target Ther. 2020 Sep 3;5(1):186
pubmed: 32883951
Biochem Biophys Res Commun. 2008 May 2;369(2):344-9
pubmed: 18279660
J Infect. 2018 Feb;76(2):186-195
pubmed: 29198606
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
Thromb Haemost. 2016 Aug 30;116(3):554-64
pubmed: 27356567
Antibodies (Basel). 2020 Jul 16;9(3):
pubmed: 32708525
Nat Rev Dis Primers. 2016 Jan 14;2:15084
pubmed: 27188830
Eur Heart J. 2010 Apr;31(7):815-23
pubmed: 20176799
J Clin Med. 2019 Jun 29;8(7):
pubmed: 31261925